Specialties

Menopause marks a major transition in a woman’s life, defined not only by the end of menstrual cycles but also by profound hormonal and metabolic changes. One often under‑recognized shift is the acceleration of cardiometabolic risk. Women in midlife frequently experience increased central adiposity, changes in glucose regulation, rising blood …

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have transformed type 2 diabetes management by improving blood sugar control and promoting weight loss. Yet as clinical use grows, so does interest in how GLP‑1 medications affect skeletal health — particularly their impact on bone density, remodeling, and fracture risk. This article unpacks …

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …

The potential link between GLP‑1 therapies and depression has sparked growing interest among clinicians and researchers. If you’ve ever wondered whether glucagon‑like peptide‑1 (GLP‑1) receptor agonists could positively influence mood, you’re not alone. Early research suggests these medications may ease depressive symptoms by dampening inflammation and influencing brain signaling, though …

Could a diabetes medication help women with PCOS regain control of their cycles and metabolism? GLP‑1 receptor agonists, best known for treating type 2 diabetes and obesity, are showing promise for women with polycystic ovary syndrome (PCOS). These medications may support weight loss, improve insulin resistance, and even lead to …

In clinical practice, patients with both type 2 diabetes and heart failure with preserved ejection fraction (HFpEF) often present with overlapping symptoms and complex care needs. The evolving landscape of cardiometabolic treatment has brought new attention to GLP‑1 HFpEF diabetes management, especially as recent evidence suggests that glucagon-like peptide‑1 receptor …

Managing type 2 diabetes in people with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD) on dialysis presents unique clinical challenges. With the 2026 Standards of Care increasingly shifting the focus toward cardio-renal outcomes, many clinicians are asking: how far can we go safely with GLP‑1 receptor agonists …

Glucagon‑like peptide‑1 (GLP‑1) receptor agonists have revolutionized type 2 diabetes and obesity treatment—but could they also impact your brain? As headlines tout possible cognitive benefits, many patients and clinicians are asking: Can GLP‑1 drugs lower dementia risk? This article breaks down what we know so far, explains the science behind …

Living with diabetes can take a serious toll on a person’s mental well-being. Depression, anxiety, and other psychiatric conditions often go hand-in-hand with chronic illnesses, and diabetes is no exception. Yet, despite the deep connection between mental health and diabetes, care for these conditions remains siloed. This article gives clinicians …

Did you know that women with diabetes have a significantly higher risk of heart disease compared to men with diabetes? While many of the standard care guidelines apply to all patients, women often face additional, underrecognized threats to their heart and metabolic health. Understanding how sex-specific factors—such as hormonal changes, …